Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
- 108 Downloads
In 2008, the US Food and Drug Administration (FDA) issued guidance requiring demonstration of cardiovascular safety for all new glucose-lowering agents intended for the treatment of type 2 diabetes. The main driver for this move was the negative experience that the FDA had encountered with rosiglitazone. This widely prescribed thiazolidinedione had come under intense pressure with publication of an analysis suggesting an increased risk of myocardial infarction. The new FDA stringency stipulated the need for randomized controlled trials involving adequate numbers of participants over sufficiently long exposure and follow-up periods with adjudicated cardiovascular endpoints assessed against specific safety limits. It has been argued that these requirements are perhaps overzealous and run the risk of reducing innovation. Aspects of the pharmaceutical industry are perceived as being increasingly risk-averse within an increasingly competitive diabetes market. Set against these concerns is an opportunity to fill much-needed gaps in knowledge about the cardiovascular risks and benefits of glucose-lowering drugs, both old and new. Five years since the issuance of the FDA guidelines, we assess the operation of the current approval processes. We set the agency’s decision making in a broader context of other major regulatory bodies. Using recent data from trials of saxagliptin, alogliptin, and canagliflozin as examples, alongside the recently announced removal of the prescribing and dispensing restrictions for rosiglitazone, we consider whether the guidelines are functioning as intended.
KeywordsRosiglitazone Major Adverse Cardiac Event Glimepiride Saxagliptin Linagliptin
Conflict of Interest
No funding was received for writing this article. Profil Institute for Clinical Research Inc. undertakes early-phase clinical studies of new therapies for diabetes and obesity. Professor Krentz and Dr Hompesch have no other potential conflicts of interest. The views expressed are those of the authors.
- 1.Krentz AJ. Rosiglitazone: trials, tribulations and termination. Drugs 2011;71:123–30.Google Scholar
- 3.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring: FDA; 2008.Google Scholar
- 5.EMA guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf). Accessed 20 Dec 2013.
- 11.FDA drug safety communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM385315.pdfre.). Accessed 25 Feb 2014.
- 12.Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. N Engl J Med 2013;369:1285–7.Google Scholar
- 18.Novo Nordisk reported to police over disclosure delay on ruling. Available from: http://www.ft.com/intl/cms/s/0/6fc97422-6171-11e3-b7f1-00144feabdc0.html?siteedition=uk#axzz30sKwfcop. Accessed 29 Dec 2013.
- 19.Gore MO, McGuire DK. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment. Diab Vasc Dis Res 2012;9:85–8.Google Scholar
- 21.Wheeler S, Moore K, Forsberg CW, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. Epub 25 Jun 2013.Google Scholar
- 22.Krentz AJ, Sinclair AJ. Do sulfonylureas still have a role in type 2 diabetes? Prescriber 2011;22:32–6.Google Scholar
- 24.ClinicalTrials.gov. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes. Available from: http://clinicaltrials.gov/show/NCT01243424. Accessed 22 Dec 2013.
- 30.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCentralPubMedCrossRefGoogle Scholar
- 31.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53.Google Scholar
- 32.Krentz AJ. Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study. In: Crepaldi GT, Avogaro A, editors. The metabolic syndrome: diabetes, obesity, hyperlipidemia and hypertension. Amsterdam: Excertpa Medical International Conference Series; 2002:261–77.Google Scholar
- 33.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65.Google Scholar
- 36.FDA Drug Safety Communication. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. 2013. Available from: http://www.fda.gov/drugs/drugsafety/ucm376389.htm.). Accessed 23 Dec 2013.
- 37.Nissen SE. Rosiglitazone: a case of regulatory hubris. BMJ. 2013;347:f7428.Google Scholar
- 39.Lincoff AM, Tardif JC, Neal B, et al. Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013;166:429–34.PubMedCrossRefGoogle Scholar
- 45.US FDA. FDA news release. FDA approves Invokana to treat type 2 diabetes. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm345848.htm. Accessed 3 Jan 2014.
- 46.ClinicalTrials.gov. CANVAS: CANagliflozin cardioVascular Assessment Study. Available from: http://clinicaltrials.gov/ct2/show/NCT01032629?term=CANVAS&rank=1. Accessed 3 Jan 2014.
- 48.Novo Nordisk. Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg®. Available from: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=83700060-0ce3-4577-a35a-f3e57801637d. Accessed 4 Jan 2014.
- 49.Insulin degludec and insulin degludec/insulin aspart treatment to improve glycemic control in patients with diabetes mellitus. NDAs 203314 and 203313. Briefing document. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdf. Accessed 23 Dec 2013
- 50.US FDA. Degludec and degludec/aspart. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, 8 Nov 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM330923.pdf. Accessed 4 Jan 2014.
- 54.White WB, Kupfer S, Cushman WC, Bakris GL, Heller SK, Bergenstal RM, et al. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Washington DC: American College of Cardiology 2014 Scientific Sessions; 2104.Google Scholar
- 56.Mullard A. Outcome results renew debate about diabetes drug development. Lancet Diabetes Endocrinol. 2013. doi: 10.1016/S2213-8587(13)70118-9.
- 57.Ledford H. Diabetes drugs ride a bumpy road. Nature. 2013;504:198.Google Scholar
- 58.Serafino P. Sanofi pulls U.S. file for lixisenatide diabetes drug. Available from: http://www.bloomberg.com/news/2013-09-12/sanofi-pulls-u-s-file-for-lixisenatide-diabetes-drug.html. Accessed 6 Jan 2014.